LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Inicio・Lista de Acciones・IQVIA Holdings Inc

IQVIA Holdings Inc

Cerrado

SectorSanidad

210.84 -0.06

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

209.68

Máximo

211.29

Métricas clave
By Trading Economics
Ingresos	66M 332M
Ventas	83M 4.1B
P/B Media del Sector	29.42 77.256
Margen de beneficios	8.098
Empleados	91,000
EBITDA	102M 883M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+12.76% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-1.1B 36B
Apertura anterior	210.9
Cierre anterior	210.84

Noticias sobre sentimiento de mercado

By Acuity

81%

19%

359 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

150.68 / 153.45 Soporte y Resistencia

IQVIA Holdings Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 nov 2025, 21:36 UTC

Ganancias

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9 nov 2025, 21:22 UTC

Ganancias

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10 nov 2025, 00:00 UTC

Charlas de Mercado

India Inflation Poised to Hit New Low -- Market Talk

9 nov 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9 nov 2025, 23:35 UTC

Charlas de Mercado

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9 nov 2025, 21:05 UTC

Ganancias

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9 nov 2025, 21:04 UTC

Ganancias

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9 nov 2025, 21:03 UTC

Ganancias

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9 nov 2025, 20:49 UTC

Ganancias

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9 nov 2025, 20:49 UTC

Ganancias

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9 nov 2025, 20:45 UTC

Ganancias

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9 nov 2025, 20:45 UTC

Ganancias

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9 nov 2025, 20:42 UTC

Ganancias

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9 nov 2025, 20:42 UTC

Ganancias

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9 nov 2025, 20:41 UTC

Ganancias

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9 nov 2025, 20:41 UTC

Ganancias

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9 nov 2025, 20:39 UTC

Ganancias

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9 nov 2025, 20:39 UTC

Ganancias

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9 nov 2025, 20:38 UTC

Ganancias

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9 nov 2025, 20:38 UTC

Ganancias

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9 nov 2025, 20:38 UTC

Ganancias

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8 nov 2025, 13:10 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov 2025, 03:50 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov 2025, 03:41 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov 2025, 03:07 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov 2025, 22:36 UTC

Ganancias

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Ganancias

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q EPS $9.89 >CSU.T

Comparación entre iguales

Cambio de precio

IQVIA Holdings Inc previsión

Precio Objetivo

By TipRanks

12.76% repunte

Estimación a 12 Meses

Media 237.31 USD 12.76%

Máximo 265 USD

Mínimo 200 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para IQVIA Holdings Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

Comprar

Mantener

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para IQVIA Holdings Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

150.68 / 153.45Soporte y Resistencia

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentimiento

By Acuity

359 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.